 |
|
| Saturday, December 12, 1998 |
| 8.30 - 9.30 | CONTRIBUTED WORKSHOPS - SESSION 2 |
| | TRACK 1: DECISION SUPPORT SYSTEMS & MODELS |
| | W11 | DECISION ANALYSIS IN CANCER THERAPY, A NEW WAY FOR EVALUATION OUTCOMES WITH THE ANALYTIC HIERARCHY PROCESS (AHP)
Reibnitz C, Silva Saavedra, M, School of Public Health, University of Bielefeld, Bielefed, Germany |
| | W12 | DEVELOPING INTERACTIVE COMPUTER SOFTWARE FOR EVALUATING THE ECONOMIC AND CLINICAL OUTCOMES OF VARIOUS TREATMENT STRATEGIES
McGhan WF, University of the Sciences in Philadelphia, Philadelphia, PA, USA |
| | TRACK 2: GUIDELINES & STANDARDS |
| | W17 | STANDARDIZATION IN THE PUBLIC HEALTH SYSTEM OF RUSSIA: THE FIRST EXPERIENCE
Vorobyev PA1, Aksyuk AV1, Yakimov OS1, Novolodsky VM1, Kuzin VF1, Kobina SA2, 1Moscow Medical Academy, Laboratory of Outcomes and Standardization Research, Moscow, Russia; 2Rhône-Poulenc Moscow Representative office, Pharmacoeconomics Department, Moscow, Russia |
| | TRACK 3: QUALITY OF LIFE ASSESSMENT |
| | W18 | COMPREHENSIVE GUIDELINES FOR INTERPRETATION AND VALIDATION OF QUALITY OF LIFE QUESTIONNAIRES
Marquis P1, Arnold B1, Conway K2, 1Mapi Values, Lyon, France, 2Mapi Research Institute, Lyon, France |
| | TRACK 4: STUDY METHODS |
| | W7 | HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS
Trippoli S, Messori A. Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy |
| | W14 | DESIGNING AN INTERNATIONAL PIGGY-BACK STUDY: PROVIDING THE FOUNDATION
Crawford B1, Evans C2, 1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, Westborough, MA, USA |
| 9.30 - 10.30 | CONTRIBUTED WORKSHOP - SESSION 2R (SESSION 2 WORKSHOPS ARE REPEATED) |
| | TRACK 1: DECISION SUPPORT SYSTEMS & MODELS |
| | W11 | DECISION ANALYSIS IN CANCER THERAPY, A NEW WAY FOR EVALUATION OUTCOMES WITH THE ANALYTIC HIERARCHY PROCESS (AHP)
Reibnitz C, Silva Saavedra, M, School of Public Health, University of Bielefeld, Bielefed, Germany |
| | W12 | DEVELOPING INTERACTIVE COMPUTER SOFTWARE FOR EVALUATING THE ECONOMIC AND CLINICAL OUTCOMES OF VARIOUS TREATMENT STRATEGIES
McGhan WF, University of the Sciences in Philadelphia, Philadelphia, PA, USA |
| | TRACK 2: GUIDELINES & STANDARDS |
| | W17 | STANDARDIZATION IN THE PUBLIC HEALTH SYSTEM OF RUSSIA: THE FIRST EXPERIENCE
Vorobyev PA1, Aksyuk AV1, Yakimov OS1, Novolodsky VM1, Kuzin VF1, Kobina SA2, 1Moscow Medical Academy, Laboratory of Outcomes and Standardization Research, Moscow, Russia; 2Rhône-Poulenc Moscow Representative office, Pharmacoeconomics Department, Moscow, Russia |
| | TRACK 3: QUALITY OF LIFE ASSESSMENT |
| | W18 | COMPREHENSIVE GUIDELINES FOR INTERPRETATION AND VALIDATION OF QUALITY OF LIFE QUESTIONNAIRES
Marquis P1, Arnold B1, Conway K2, 1Mapi Values, Lyon, France, 2Mapi Research Institute, Lyon, France |
| | TRACK 4: STUDY METHODS |
| | W7 | HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS
Trippoli S, Messori A. Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy |
| | W14 | DESIGNING AN INTERNATIONAL PIGGY-BACK STUDY: PROVIDING THE FOUNDATION
Crawford B1, Evans C2, 1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, Westborough, MA, USA |
| 10.30 - 12.00 | THIRD GENERAL SESSION |
| | Developing Consensus on Educational Standards, Pharmacoeconomic Evaluations Reporting and Code of Ethics
Moderator: Jonathan Cooke MPharm, PhD, South Manchester University Hospitals, Manchester, England, UK
REPORT FROM THE ISPOR US CONSENSUS DEVELOPMENT ADVISORY PANELS ON EDUCATION STANDARDS, CODE OF ETHICS, AND STANDARDIZED REPORTING OF PHARMACOECEONOMICS AND OUTCOMES RESEARCH
Speaker: Jean Paul Gagnon PhD, Director Health Economics Policy, Hoechst Marion Roussel, Kansas City, MO, USA and ISPOR Consensus Development Chair
DEVELOPING CONSENSUS ON EDUCATION STANDARDS, CODE OF ETHICS, AND STANDARDIZED REPORTING OF PHARMACOECEONOMICS AND OUTCOMES RESEARCH - A CRITIQUE OF THE US PANEL REPORTS FROM A EUROPEAN PERSPECTIVE
Speakers: The European Panel
- Werner Brouwer MD, The Netherlands
- Jonathan Cooke MPharm, PhD, MPharm, South Manchester University Hospitals, Manchester, UK
- Michael Drummond PhD, University of York, Centre for Health Economics, York, UK
- Livio Garattini MD, CESAV Centre for Health Economics, Institute for Pharmacological Research, Ranica, Italy
- Bengt G. Jönsson MA, PhD, Stockholm School of Economics, Stockholm, Sweden (invited)
- Karl W. Lauterbach MD, ScD, Institute for Health Economics, University of Cologne, Cologne, Germany
- Frank Peys PhD, Belgium Institute for Health Economics, Brussels, Belgium
- Claude Le Pen PhD, Université Paris-Dauphine, Paris, France
- Hugo Robays, University Hospital Gent, Gent, Belgium
- Joan Rovira PhD, SOIKOS, Department of Economics, University of Barcelona, Barcelona, Spain
- J.Matthias Graf von Schulenberg PhD, Centre for Health Economics and Health System-HSR, University of Hannover, Hannover, Germany
|
| 12.00 - 13.00 | LUNCH & VIEWING CONTRIBUTED POSTER PRESENTATIONS - SESSION 2 |
| 13.00 - 14.00 | CONTRIBUTED WORKSHOPS - SESSION 3 |
| | TRACK 1: DECISION SUPPORT SYSTEMS & MODELS |
| | W4 | MONTE CARLO SIMULATION IN HEALTH CARE MODELS
Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA |
| | W6 | The Appropriateness of Common Medical Data Sources: Randomized Trials, Meta-Analyses, Epidemiological and Observational Studies for Pharmacoeconomic Analyses
Hasford J, Sangha O, Department of Medical Informatics, Biometry and Epidemiology, University of Munich, School of Medicine, Munich, Germany |
| | TRACK 3: QUALITY OF LIFE ASSESSMENT |
| | W13 | THE USE OF PROXIES TO COLLECT HEALTH CARE RESOURCES AND QUALITY OF LIFE DATA
Crawford B1, Evans C2, Abetz L3, 1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, Westborough, MA, USA; 3MAPI Values, Cheshire, UK |
| | TRACK 4: STUDY METHODS |
| | W2 | ESTIMATING DRUG EFFECTS: FROM CLINICAL TRIAL RESULTS TO ACTUAL PRACTICE
Caro JJ1, Migliaccio-Walle K1, Thizon de Gaulle I2, Coniglio A2, 1 Caro Research, Concord, MA, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Sanofi, Paris, France |
| | W3 | ESTIMATING POPULATION BUDGET AND HEALTH IMPACTS OF NEW TREATMENTS
Mauskopf J, Research Triangle Institute, Research Triangle Park, NC, USA |
| | W9 | ECONOMIC EVALUATION OF REHABILITATION PROGRAMS: THE PERSPECTVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY
Seitz R1, Wasem J2, Krauth C3, 1Department for Health Economics, University of Ulm, Ulm, Germany; 2Institute for Medical Information Management, Biometrics and Epidemiology, University of Munich, Munich, Germany; 3Department for Social Medicine and Epidemiology, University of Hannover, Hannover, Germany |
| 14.00 - 15.00 | CONTRIBUTED WORKSHOPS - SESSION 3R (SESSION 3 WORKSHOPS ARE REPEATED) |
| | TRACK 1: DECISION SUPPORT SYSTEMS & MODELS |
| | W4 | MONTE CARLO SIMULATION IN HEALTH CARE MODELS
Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA |
| | W6 | THE APPROPRIATENESS OF COMMON MEDICAL DATA SOURCES: RANDOMIZED TRIALS, META-ANALYSES, EPIDEMIOLOGICAL AND OBSERVATIONAL STUDIES FOR PHARMACOECEONOMIC ANALYSES
Hasford J, Sangha O, Department of Medical Informatics, Biometry and Epidemiology, University of Munich, School of Medicine, Munich, Germany |
| | TRACK 3: QUALITY OF LIFE ASSESSMENT |
| | W13 | THE USE OF PROXIES TO COLLECT HEALTH CARE RESOURCES AND QUALITY OF LIFE DATA
Crawford B1, Evans C2, Abetz L3, 1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, Westborough, MA, USA; 3MAPI Values, Cheshire, UK |
| | TRACK 4: STUDY METHODS |
| | W2 | ESTIMATING DRUG EFFECTS: FROM CLINICAL TRIAL RESULTS TO ACTUAL PRACTICE
Caro JJ1, Migliaccio-Walle K1, Thizon de Gaulle I2, Coniglio A2, 1 Caro Research, Concord, MA, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Sanofi, Paris, France |
| | W3 | ESTIMATING POPULATION BUDGET AND HEALTH IMPACTS OF NEW TREATMENTS
Mauskopf J, Research Triangle Institute, Research Triangle Park, NC, USA |
| | W9 | ECONOMIC EVALUATION OF REHABILITATION PROGRAMS: THE PERSPECTVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY
Seitz R1, Wasem J2, Krauth C3, 1Department for Health Economics, University of Ulm, Ulm, Germany; 2Institute for Medical Information Management, Biometrics and Epidemiology, University of Munich, Munich, Germany; 3Department for Social Medicine and Epidemiology, University of Hannover, Hannover, Germany |
| 15.00 - 16.30 | FOURTH GENERAL SESSION |
| | Using Disease Management to Deliver Cost-Effective Health Care - Focusing on Diabetes
Moderator: Karl Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne
DIABETES MANAGEMENT IN US MANAGED CARE HEALTH PLANS
Speaker: Gregory P. Gilmet MD, MPH, Medical Director, Quality Management, Blue Care Network of Michigan, Southfield, MI, USA
DIABETES DISEASE MANAGEMENT PROGRAMS THAT WORK AND THOSE THAT DON'T WORK
Speaker: Jean-Philippe Assal MD, WHO Collaborating Centre for Reference and Research in Diabetes Education, University Hospital, Geneva, Switzerland
WORKING AT THE POPULATION LEVEL: THE PERSPECTIVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY
Speaker: Andrew Morris, MD, Direcor of Diabetes Research, MEMO, Ninewells Hospital and Medical School, Dundee Teaching Hospitals, Dundee, Scotland, UK |
| 16.30 - 17.00 | CLOSING REMARKS |
| | Speakers: ISPOR Conference Co-chairs |
European Conference Main Page
|
|
|
